Aethlon Medical, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2024, compared with fiscal 2023. The filing was signed June 27, 2024; it is an annual report, not a quarterly report.
Business context
Aethlon is a clinical-stage medical therapeutic company developing the Hemopurifier, an extracorporeal device intended to remove viruses and extracellular vesicles from blood. The company is pursuing potential applications in cancer, life-threatening viral infections, and organ transplantation. The device is not approved for commercial sale in the United States or elsewhere. The FDA has granted Breakthrough Device designation for cancer and certain life-threatening viral indications; this does not guarantee approval.
Financial performance and position
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $0 | $574,245 |
| Operating expenses | $12,636,568 | $12,472,883 |
| Operating loss | $12,636,568 | $11,898,638 |
| Net loss | $12,208,174 | $12,029,786 |
| Net loss per share, basic and diluted | $4.86 | $5.86 |
| Cash used in operating activities | $10.13 million | $10.51 million |
- Revenue fell to zero after the NIH melanoma contract ended; the prior-year revenue was the final $574,245 recognized during contract close-out.
- Research and development expense was approximately $2.52 million, down from $2.75 million. Gross margin is not meaningful given no FY2024 revenue.
- At March 31, 2024, cash and cash equivalents were $5.44 million, working capital was $4.40 million, total assets were $8.25 million, and total liabilities were $2.48 million. The filing does not identify interest-bearing debt; reported lease liabilities totaled about $940,000.
- Cash and restricted cash declined $9.09 million during FY2024. Investing activities used $251,000; financing activities provided $1.29 million, versus $8.91 million in FY2023.
- FY2024 expenses rose $164,000. Payroll and related expense increased $763,000, including $862,000 of higher separation expense for a former executive; lower general and administrative expense and professional fees partly offset the increase.
Material changes, outlook, and risks
- Funding and going concern: Management and the auditor cite substantial doubt about the company’s ability to continue as a going concern. Management states that cash may not fund operations for 12 months beyond the financial-statement issuance date and expects continued losses and negative operating cash flow. Additional capital is required, with no assurance it will be available.
- Subsequent financing: A May 2024 public offering generated approximately $4.7 million gross, before fees and expenses, through common shares and warrants. In June, warrant exercises generated a further $1.84 million. The filing reports cash and cash equivalents above $9.1 million after these events. These transactions materially increased potential and actual share dilution.
- Clinical and manufacturing progress: FDA approval in April 2024 allowed manufacturing at the company’s San Diego facility. In June 2024, an Australian ethics committee approved the proposed Phase 1 oncology trial; other site approvals remained in process. A planned change to a second GNA supplier remained subject to FDA review. The U.S. COVID-19 feasibility study was terminated in 2022 for insufficient ICU patients; the India COVID-19 study remained open, with one patient treated.
- Other risks: Results depend on clinical trial progress, regulatory approvals, patient recruitment, supplier continuity, manufacturing execution, and future financing. The company also cites competitive, reimbursement, intellectual-property, product-liability, and Nasdaq-listing risks.
- Nasdaq: The company received a June 27, 2024 notice for noncompliance with the $1.00 minimum bid-price rule and had until December 24, 2024 to regain compliance, subject to a possible extension.
- Controls and unusual items: Management found internal control over financial reporting ineffective due to a material weakness in segregation of duties and financial-system access controls. The company also reversed a roughly $404,000 accrued commission liability from prior years through equity in FY2024; this was not reported as revenue.
- Audit and legal: The auditor issued an unqualified opinion on the financial statements, with a going-concern uncertainty paragraph and no critical audit matters. The company reported no pending litigation.
Important facts for investors to verify
- Latest cash balance, post-offering cash runway, operating burn, and management’s financing assumptions.
- Share count and fully diluted capitalization after the May offering, pre-funded warrants, and June warrant exercises.
- Clinical-trial start dates, enrollment, safety and efficacy data, and remaining ethics or regulatory approvals.
- FDA status and timing for qualification of the second GNA supplier and any resulting manufacturing constraints.
- Progress in remediating the material weakness and Nasdaq bid-price compliance status.
- The reported loss per share: the consolidated statements show $4.86 for FY2024 and $5.86 for FY2023; a share-based compensation note elsewhere in the filing presents different per-share figures, which investors should reconcile.